Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: Role of dopamine transporter

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 7, 2007, Pages 1478-1486

  Fachinetto, Roselei ^a   Villarinho, Jardel G ^a   Wagner, Caroline ^a   Pereira, Romaiana P ^a   Ávila, Daiana Silva ^a   Burger, Marilise E ^a   Calixto, João Batista ^b   Rocha, João B T ^a   Ferreira, Juliano ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Dopamine uptake; Haloperidol; Medicinal plant; Oxidative stress; Tardive dyskinesia; V. officinalis

Indexed keywords

DOPAMINE TRANSPORTER; HALOPERIDOL DECANOATE; VALERIAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE UPTAKE; EVALUATION; HERB; LOCOMOTION; LONG TERM CARE; MALE; MASTICATION; MAZE TEST; MULTIPLE CYCLE TREATMENT; NONHUMAN; OPEN FIELD TEST; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; PREVALENCE; RAT; SLEEP; VACOUS CHEWING MOVEMENT; VALERIANA OFFICINALIS; WISTAR RAT;

EID: 84983724523     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.06.028     Document Type: Article

References (76)

1. Abílio V.C., Silva R.H., Carvalho R.C., Grassl C., Calzavara M.B., Registro S., et al. Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia. Neuropharmacology 47 (2004) 263-272
2. Abourashed E.A., Koetter U., and Brattstrom A. In vitro binding experiments with a Valerian, hops and their fixed combination extract (Ze91019) to selected central nervous system receptors. Phytomedicine 11 (2004) 633-638
3. Al-Majed A.A., Al-Yahya A.A., Al-Bekairi A.M., Al-Shabanah O.A., and Qureshi S. Studies on the cytological and biochemical effects of valerian in somatic and germ cells of Swiss albino mice. Food Chem Toxicol 44 (2006) 1830-1837
4. Andreassen O.A., and Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?. Prog Neurobiol 61 (2000) 525-541
5. Andreassen O.A., Ferrante R.J., Aamo T.O., Beal M.F., and Jorgensen H.A. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 122 (2003) 717-725
6. Araujo N.P., Abilio V.C., Silva R.H., Pereira R.C., Carvalho R.C., Gonzalez C., et al. Effects of topiramate on oral dyskinesia induced by reserpine. Brain Res Bull 64 (2005) 331-337
7. Beckman M.L., and Quick M.W. Neurotransmitter transporters: regulators of function and functional regulation. J Membr Biol 164 (1998) 1-10
8. Boomershine K.H., Shelton P.S., and Boomershine J.E. Vitamin E in the treatment of tardive dyskinesia. Ann Pharmacother 33 (1999) 1195-1202
9. Broadhurst P.L. Experiments in psychogenetics. In: Eysenk H.J. (Ed). Experiments in personality (1960), Routledge & Kegan Paul, London 76
10. Brown K., Reid A., White T., Henderson T., Hukin S., Johnstone C., et al. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol Psychiatry 43 (1998) 863-867
11. Burger M.E., Alves A., Callegari L., Athayde F.R., Nogueira C.W., Zeni G., et al. Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 135-140
12. Burger M.E., Fachinetto R., Calegari L., Paixão M.W., Braga A.L., and Rocha J.B.T. Effects on age on orofacial dyskinesia reserpine-induced and possible protection of diphenyl-diselenide. Brain Res Bull 64 (2004) 339-345
13. Burger M.E., Fachinetto R., Zeni G., and Rocha J.B.T. Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacol Biochem Behav 81 (2005) 608-615
14. Burger M.E., Fachineto R., Alves A., Callegari L., and Rocha J.B. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res 1031 (2005) 202-210
15. Burt D., Creese I., and Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196 (1977) 326-327
16. Cadet J.L., Lohr J.B., and Jeste D.V. Free radical and tardive dyskinesia. Trends Neurosci 9 (1986) 107-108
17. Cadet J.L., Lohr J.B., and Jeste D.V. Tardive dyskinesia and schizophrenic burnout: the possible involvement of cytotoxic free radicals. In: Henn F.A., and DeLisi L.E. (Eds). Handbook of schizophrenia: the neurochemistry and pharmacology of schizophrenia (1987), Elsevier, Amsterdam 425-438
18. Carobrez A.P., and Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 29 (2005) 1193-1205
19. Casey D.E. Tardive dyskinesia: reversible and irreversible. Psychopharmacology 2 (1985) 88-97
20. Cavallero R., and Smeraldi E. Antipsychotic-induced tardive dyskinesia: recognition, prevention and management. CNS Drugs 4 (1995) 278-293
21. Chopin P., Stenger A., Couzinier J.P., and Briley M. Indirect dopaminergic effects of tofisopam, a 2,3-benzodiazepine, and their inhibition by lithium. J Pharm Pharmacol 37 (1985) 917-919
22. Crane G.E. Persistent dyskinesia. Br J Psychiatry 122 (1973) 395-405
23. Creese I., Burt D., and Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192 (1976) 481-483
24. Della Loggia R., Tubaro A., and Redaelli C. Evaluation of the activity on the mouse CNS of several plant extracts and a combination of them. Riv Neurol 51 (1981) 297-310
25. Egan M.F., Hurd Y., Hyde T.M., Weinberger D.R., Wyatt R.J., and Kleinman J.E. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse 18 (1994) 178-189
26. Fachinetto R., Burger M.B., Wagner C., Wondracek D.C., Brito V.B., Nogueira C.W., et al. High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats. Pharmacol Biochem Behav 81 (2005) 585-592
27. Faria R.R., Abilio V.C., Grassl C., Chinen C.C., Negrao L.T., de Castro J.P., et al. Beneficial effects of vitamin C and vitamin E on reserpine-induced oral dyskinesia in rats: critical role of striatal catalase activity. Neuropharmacology 48 (2005) 993-1001
28. Fibiger H.C., and Lloyd K.G. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 7 (1984) 462-464
29. Fugh-Berman A., and Cott J.M. Dietary supplements and natural products as psychotherapeutic agents. Psychosom Med 61 (1999) 712-728
30. Gunne L., Häggström J., and Sjöquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 309 (1984) 347-349
31. Hashimoto K., Tsukada H., Nishiyama S., Fukumoto D., Kakiuchi T., Shimizu E., et al. Protective effects of N-acetyl-l-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology 29 (2004) 2018-2023
32. 3H-dopamine into synaptosomes from rat striatum. Mol Pharmacol 10 (1974) 746-758
33. Huang C.L., Huang N.K., Shyue S.K., and Chern Y. Hydrogen peroxide induces loss of dopamine transporter activity: a calcium-dependent oxidative mechanism. J Neurochem 86 (2003) 1247-1259
34. Jeste D.V., Potkin S.G., Sinhá S., Feder S., and Wyatt R.J. Tardive dyskinesia-reversible and persistent. Arch Gen Psychiatry 36 (1979) 585-590
35. Kahlig K.M., and Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol 479 (2003) 153-158
36. Kane J.M. Tardive dyskinesia: epidemiology and clinical presentation. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: the fourth generation of progress vol. 39 (1995), Raven Press, New York 1485-1495
37. Kane J.M., and Smith J.M. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39 (1982) 473-481
38. Kaneda H., Shirakawa O., Dale J., Goodman L., Bachus S.E., and Tamminga C.A. Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats. Eur J Pharmacol 121 (1992) 43-49
39. Kennedy D.O., Little W., Haskell C.F., and Scholey A.B. Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytother Res 20 (2006) 96-102
40. Klawans Jr. H.L., and Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm 33 (1972) 235-246
41. Lee S., Oh D., Jung S., Kim Y., Cho H., Koh J., et al. Neuroleptic drugs alter the dopamine transporter-mediated uptake and release of dopamine: a possible mechanism for drug-induced tardive dyskinesia. Pharmacol Res 35 (1997) 446-450
42. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 86 (1990) 464-478
43. Lohr J.B. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry 48 (1991) 1097-1106
44. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., and Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 28 (1990) 535-539
45. Lohr J.B., Kuczenski R., and Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17 (2003) 47-62
46. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265
47. McCabe S. Complimentary herbal and alternative drugs in clinical practice. Perspect Psychiatr Care 38 (2002) 98-107
48. Mennini T., Bernasconi P., Bombardelli E., and Morazzoni P. In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in the rat brain. Fitoterapia 64 (1993) 291-300
49. Misra H.P., and Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and simple assay for superoxide dismutase. J Biol Chem 247 (1972) 3170-3175
50. Morazzoni P., and Bombardelli E. Valeriana offcinalis: traditional use and recent evaluation of activity. Fitoterapia 66 (1995) 99-112
51. Morselli P.L., Fournier V., Bossi L., and Musch B. Clinical activity of GABA agonists in neuroleptic- and l-dopa-induced dyskinesia. Psychopharmacology 2 (1985) 128-136
52. Naidu P.S., Singh A., and Kulkarni S.K. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology 44 (2003) 1100-1106
53. Ohkawa H., Ohishi H., and Yagi K. Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Anal Biochem 95 (1979) 351-358
54. Oliva I., Gonzalez-Trujano M.E., Arrieta J., Enciso-Rodriguez R., and Navarrete A. Neuropharmacological profile of hydroalcohol extract of Valeriana edulis ssp. procera roots in mice. Phytother Res 18 (2004) 290-296
55. 3H]GABA release. Neurochem Res 24 (1999) 1373-1378
56. Pall H.S., Williams A.C., Blake D.R., and Lunee J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 2 (1987) 596-599
57. Peixoto M.F., Araújo N.P., Silva R.H., Castro J.P., Fukushiro D.F., Faria R.R., et al. Effects of gabaergic drugs on reserpine-induced oral dyskinesia. Behav Brain Res 160 (2004) 51-59
58. Pellow S., Chopin P., File S.E., and Briley M. Validation of open: closed arms entries in elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14 (1985) 149-167
59. Pérez-Severiano P., Rodríguez-Pérez M., Pedraza-Chaverrí J., Maldonado P.D., Medina-Campos O.N., Ortíz-Plata A., et al. S-Allylcysteine, a garlic-derived antioxidant, ameliorates quinolinic acid-induced neurotoxicity and oxidative damage in rats. Neurochem Int 45 (2004) 1175-1183
60. Raghavendra V., Naidu P.S., and Kulkarni S.K. Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors. Brain Res 904 (2001) 149-152
61. Rosengarten H., Bartoszyk G.D., Quartermain D., and Lin Y. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 273-279
62. Rubinstein M., Muschietti J.P., Gershanik O., Flawia M.M., and Stefano F.J. Adaptative mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treated mice. J Pharmacol Exp Ther 252 (1990) 810-816
63. Sachdev P., Saharov T., and Cathcart S. The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia. Biol Psychiatry 46 (1999) 1672-1681
64. Sakamoto T., Mitani Y., and Nakajima K. Psychotropic effects of Japanese valerian root extract. Chem Pharm Bull 40 (1992) 758-761
65. Saldaña M., Bonastre M., Aguilar E., and Marin C. Differential nigral expression of Bcl-2 protein family in chronically haloperidol and clozapine-treated rats: role in neurotoxicity and stereotyped behavior. Exp Neurol 203 (2006) 302-308
66. Santos M.S., Ferreira F., Cunha A.P., Carvalho A.P., and Macedo T. An aqueous extract of valerian influences the transport of GABA in synaptosomes. Planta Med 60 (1994) 278-279
67. 1 binding site correlates of haloperidol-induced oral dyskinesias in rat. Exp Neurol 127 (1994) 62-69
68. Shivakumar B.R., and Ravindratnath V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther 265 (1993) 1137-1141
69. Singh A., Naidu P.S., and Kulkarni S.K. Possible antioxidant and neuroprotective mechanisms of FK-506 in attenuating haloperidol-induced orofacial dyskinesia. Eur J Pharmacol 477 (2003) 87-94
70. Tamminga C.A., Crayton J.W., and Chase T.N. Improvement in tardive dyskinesia after muscimol therapy. Arch Gen Psychiatry 36 (1979) 595-598
71. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., and Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 155 (1998) 1207-1213
72. Vorbach E.U., Gortelmayer R., and Bruning J. Therapie von Insomnien: Wirksamkeit und Vertrag-lichkeit eines Baldrian-Praparates. Psychopharmakotherapie 3 (1996) 109-115
73. Woerner M.G., Kane J.M., Lieberman J.A., Alvir J., Bergmann K.J., Borenstein M., et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 11 (1991) 34-42
74. Yan L.J., Traber M.G., and Packer L. Spectrophotometric method for determination of carbonyls in oxidatively modified apolipoprotein B of human low-density lipoproteins. Anal Biochem 228 (1995) 349-351
75. Yassa R., and Jeste D.V. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 18 (1992) 701-715
76. Yoder K.K., Hutchins G.D., Morris E.D., Brashear A., Wang C., and Shekhar A. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res 71 (2004) 371-375